Skip to main content Skip to search Skip to main navigation
 Get a free Melatonin Spray with purchases over €100  Get a free Melatonin Spray with purchases over €100 X
Menu
Premium Nahrungsergänzungsmittel | artgerecht

Erenumab – Uses, Dosage & Side Effects

Erenumab is a monoclonal antibody used for the preventive treatment of migraine in adults. It blocks the CGRP receptor, reducing the frequency and severity of migraine attacks.

Regular tips about health Regular tips about health
Lexicon Navigation

Things worth knowing about "Erenumab"

Erenumab is a monoclonal antibody used for the preventive treatment of migraine in adults. It blocks the CGRP receptor, reducing the frequency and severity of migraine attacks.

What is Erenumab?

Erenumab is a monoclonal antibody approved for the preventive (prophylactic) treatment of migraine in adults. It is a biologic medication that specifically targets a key mechanism involved in triggering migraine attacks. Erenumab is marketed under the brand name Aimovig and is approved by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

Mechanism of Action

Erenumab works by binding specifically to the CGRP receptor (Calcitonin Gene-Related Peptide receptor). CGRP is a neuropeptide that plays a critical role in the pathophysiology of migraine: it is released in elevated concentrations during a migraine attack and causes dilation of blood vessels and neurogenic inflammation around the meninges, resulting in pain. By blocking the CGRP receptor, erenumab prevents CGRP from binding and exerting its pain-promoting effects, thereby reducing the frequency and intensity of migraine attacks.

Indications

Erenumab is approved for the prophylaxis of migraine in adults who experience at least 4 migraine days per month. It is used in:

  • Episodic migraine (up to 14 migraine days per month)
  • Chronic migraine (15 or more headache days per month, of which at least 8 have migraine characteristics)

Erenumab is not intended for the acute treatment of migraine attacks; it is used exclusively for prevention.

Dosage and Administration

Erenumab is administered as a subcutaneous injection (under the skin) once monthly. The recommended starting dose is 70 mg per month. For patients who do not achieve sufficient response, the dose may be increased to 140 mg per month. After appropriate training by a healthcare professional, the injection can be self-administered by the patient or given by a caregiver.

Side Effects

Erenumab is generally well tolerated. The most common side effects include:

  • Injection site reactions (redness, swelling, pain)
  • Constipation, occasionally severe
  • Muscle cramps
  • Nausea
  • Itching (pruritus)

In rare cases, allergic reactions may occur. Patients with known hypersensitivity to the active substance or any of the excipients should not use erenumab.

Contraindications and Special Considerations

Erenumab is not recommended during pregnancy or breastfeeding, as adequate safety data in humans are not yet available. Women of childbearing potential should use reliable contraception during treatment. Caution is advised in patients with severe renal or hepatic impairment. Concurrent medications should always be discussed with a healthcare provider to rule out interactions.

Clinical Efficacy

Multiple large Phase III clinical trials have demonstrated that erenumab significantly reduces the number of monthly migraine days compared to placebo. In episodic migraine, an average reduction of 3 to 4 days per month was observed; in chronic migraine, reductions of up to 6 days per month were reported. Approximately 40 to 50% of patients achieved at least a 50% reduction in monthly migraine days.

References

  1. European Medicines Agency (EMA): Aimovig (Erenumab) – Summary of Product Characteristics and Assessment Report. EMA, 2018. https://www.ema.europa.eu/en/medicines/human/EPAR/aimovig
  2. Goadsby PJ, Reuter U, Hallström Y et al.: A Controlled Trial of Erenumab for Episodic Migraine. New England Journal of Medicine, 2017; 377(22): 2123–2132.
  3. U.S. Food and Drug Administration (FDA): Aimovig (Erenumab-aooe) – Prescribing Information. FDA, 2018. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761077

Most purchased products

Discount
natural iron supplement premium plantderived mineralcomplex?ts=1751927698

Average rating of 4.94 out of 5 stars

Natural Iron

For your iron balance

Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
UV glass
Lab tested
Non-GMO
No additives
Cologne List
Gluten free
Lactose free
100% vegetarian fermentation
30 Capsules
30 Capsules
Sale price: €29.90 Regular price: €35.90
Product Quantity: Enter the desired amount or use the buttons to increase or decrease the quantity.
Discount
lactoferrin kapseln 60 premium eisenbindung immunschutz laktosefrei milch?ts=1751997240

Average rating of 4.85 out of 5 stars

Lactoferrin 60 Capsules

For your universal protection

As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
UV glass
Lab tested
Non-GMO
No additives
Cologne List
Lactose free
Pure CLN
60 Capsules
60 Capsules
Sale price: €50.00 Regular price: €59.90
Product Quantity: Enter the desired amount or use the buttons to increase or decrease the quantity.
floral lactoferrin cln mundflora lutschtabletten?ts=1779887262

Average rating of 4.96 out of 5 stars

Floral

For Healthy Oral Flora & Dental Care

Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
Sugar free
Lab tested
Non-GMO
Cologne List
Lactose free
Tooth friendly
GMP Quality
Clinical proofed
Pure CLN
30 lozenges
Regular price: €22.90
Product Quantity: Enter the desired amount or use the buttons to increase or decrease the quantity.

The latest entries

3 Posts in this encyclopedia category

Alectinib

Alectinib is a targeted cancer medication used to treat ALK-positive non-small cell lung cancer. It selectively inhibits the ALK protein, thereby slowing tumor growth.

Distorsion

A distorsion is a joint injury caused by excessive stretching or twisting, damaging ligaments, tendons, or the joint capsule without fracturing the bone.

Encorafenib

Encorafenib is a targeted cancer drug used in certain types of melanoma and colorectal cancer. It inhibits the mutated BRAF protein, thereby slowing tumor growth.

Related search terms: Erenumab